Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ABILIFY MYCITE KIT vs ALBENDAZOLE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.
Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.
Schizophrenia,Acute manic/mixed episodes associated with bipolar I disorder,Maintenance treatment of bipolar I disorder,Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Cystic hydatid disease (Echinococcus granulosus),Neurocysticercosis (Taenia solium),Giardiasis (off-label),Cutaneous larva migrans (off-label),Trichuriasis (off-label),Ascariasis (off-label),Hookworm infections (off-label)
Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.
400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.
Aripiprazole: 75 hours (range 48–146 h). Dehydro-aripiprazole: 94 hours (range 48–206 h). Steady state reached in 14 days.
Terminal half-life of albendazole sulfoxide is 8–12 hours; parent drug half-life is <1 hour. Clinical context: supports once- or twice-daily dosing.
Aripiprazole is metabolized primarily by CYP2D6 and CYP3A4. The major active metabolite is dehydro-aripiprazole (formed by CYP2D6). Phase I reactions include dehydrogenation and hydroxylation. Phase II glucuronidation of hydroxylated metabolites occurs.
Primarily hepatic via microsomal enzymes; undergoes oxidation to albendazole sulfoxide (active metabolite) by CYP3A4 and flavin-containing monooxygenases (FMO). Further metabolized to albendazole sulfone (inactive) and other oxidative metabolites.
Aripiprazole: ~25% renal, ~55% fecal; unchanged drug accounts for <1% renal. Dehydro-aripiprazole (active metabolite): excreted similarly.
Primarily renal (80%) as inactive metabolites; <2% unchanged in urine. Biliary/fecal excretion accounts for ~20%.
Aripiprazole: >99% bound to albumin and alpha-1-acid glycoprotein. Dehydro-aripiprazole: >99% bound.
70% bound to plasma proteins, primarily albumin.
Aripiprazole: 4.9 L/kg (IV). High Vd indicates extensive tissue distribution.
0.2–0.6 L/kg, indicating distribution into tissues; concentrates in liver, bile, and cerebrospinal fluid.
Oral: 87% (absolute). Tablet and orally disintegrating tablet are bioequivalent.
Oral bioavailability is low (~5%) due to extensive first-pass metabolism; co-administration with a high-fat meal increases bioavailability up to 4–5-fold.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not recommended for severe renal impairment (Cr Cl <15 m L/min) due to lack of data.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <15 m L/min), use with caution; consider dose reduction or extended intervals. No specific GFR-based guidelines available.
Child-Pugh Class A or B: No dose adjustment necessary. Child-Pugh Class C: Use with caution; maximum dose 10 mg/day due to increased exposure.
Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment (Child-Pugh A or B), use with caution; monitor liver function. No specific dose adjustment guidelines available.
Not approved for patients <18 years; safety and effectiveness not established.
For children >2 years: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for most indications. For neurocysticercosis: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 8-30 days. For hydatid disease: 15 mg/kg/day orally in 2 divided doses (max 800 mg/day) for 28-day cycles with 14-day drug-free intervals. For children <2 years: safety and efficacy not established.
No specific dose adjustment; use lower starting doses (e.g., 5 mg/day) due to increased sensitivity and risk of adverse effects, especially orthostatic hypotension and tardive dyskinesia.
No specific dose adjustment recommended; use with caution due to potential age-related hepatic or renal impairment. Monitor liver function and blood counts regularly.
WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Aripiprazole is not approved for the treatment of patients with dementia-related psychosis.
Albendazole may cause fetal harm when administered to pregnant women. It is contraindicated in pregnancy and should not be used in women who are or may become pregnant. Women of childbearing potential should have a negative pregnancy test before starting treatment and should use effective contraception during therapy and for one month after completion.
Neuroleptic malignant syndrome,Tardive dyskinesia,Metabolic changes including hyperglycemia/diabetes, dyslipidemia, weight gain,Orthostatic hypotension,Falls,Leukopenia/neutropenia/agranulocytosis,Seizures,Body temperature regulation impairment,Dysphagia,Suicidal thoughts/behaviors in adolescents/young adults with MDD
Bone marrow suppression: Monitor CBC at start and periodically; risk of pancytopenia, particularly in patients with hepatic disease or receiving high doses.,Hepatotoxicity: Monitor liver function tests due to risk of elevated transaminases and rare hepatic failure.,Risk of neurocysticercosis exacerbation: May cause increased intracranial pressure or seizures; treat with corticosteroids and anticonvulsants as needed.,Retinal damage: In ocular neurocysticercosis, evaluate for retinal lesions before therapy due to risk of retinal damage from inflammation.,Renal impairment: Use with caution; dose adjustment may be necessary.,Lactation: Excreted in breast milk; caution in nursing mothers.
Hypersensitivity to aripiprazole or any component of the formulation,Concurrent use with ziprasidone (QT prolongation risk)
Pregnancy (absolute),Known hypersensitivity to albendazole or any of its components,Patients with pre-existing bone marrow suppression (relative)
No specific food interactions are reported for the sensor component. Aripiprazole can be taken with or without food. However, avoid excessive alcohol consumption as it may increase central nervous system depression or worsen side effects. Grapefruit and grapefruit juice do not significantly interact with aripiprazole metabolism (CYP3A4 minor pathway); no restriction needed.
Take with a high-fat meal (≥40 g fat) to significantly increase oral bioavailability. Avoid grapefruit juice as it may affect drug metabolism. No specific dietary restrictions otherwise.
First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimester: Neonates exposed to antipsychotics (including aripiprazole) during late pregnancy may experience extrapyramidal symptoms and/or withdrawal symptoms (agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder).
FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal harm; avoid use unless benefit outweighs risk.
Aripiprazole is present in human breast milk; limited data suggest infant serum levels are low but can vary. M/P ratio not established. Caution advised; monitor infant for sedation, irritability, and feeding problems.
Excreted in breast milk; M/P ratio not established. Use with caution, especially in neonates due to risk of bone marrow suppression.
No specific dose adjustment recommended; however, pregnancy may alter aripiprazole pharmacokinetics (decreased exposure due to increased volume of distribution and clearance). Monitor clinical response and consider dose adjustment if efficacy or tolerability changes. Use lowest effective dose.
No specific dose adjustment recommended in pregnancy; pharmacokinetic changes not well studied. Use lowest effective dose and shortest duration possible.
Abilify My Cite is aripiprazole tablets embedded with an ingestible sensor (Ingestible Event Marker, IEM) that communicates with a wearable patch to record medication ingestion. It is used for schizophrenia, bipolar I disorder, and as adjunctive therapy for major depressive disorder. The sensor does not monitor drug levels or efficacy; it only confirms ingestion. Ensure the patient has a compatible smartphone and the My Cite app. The patch must be replaced weekly. Avoid MRI, CT, or diathermy near the patch; remove if undergoing these procedures. Monitor for aripiprazole side effects: akathisia, metabolic changes, tardive dyskinesia, and neuroleptic malignant syndrome. The ingestible sensor contains copper, magnesium, and silicon; allergy risk is low but possible.
Albendazole is a broad-spectrum anthelmintic that inhibits microtubule polymerization by binding to beta-tubulin. It is highly effective against Echinococcus granulosus cysts but requires prolonged therapy (e.g., 28-day cycles). Monitor liver function tests (LFTs) at baseline and every 2 weeks due to risk of hepatotoxicity. For neurocysticercosis, co-administer corticosteroids to reduce inflammatory reaction from cyst degeneration. Albendazole is pregnancy category C; avoid in first trimester and in women planning pregnancy within 1 month of therapy. Absorption is enhanced by a fatty meal; administer with a high-fat meal to increase bioavailability up to 5-fold.
Take Abilify My Cite by mouth as directed. The sensor in the tablet activates upon contact with stomach fluid. Wear the My Cite patch on your left upper abdomen, replacing it weekly. Use the My Cite app to scan the tablet's QR code and confirm ingestion. Do not crush or chew the tablet. If a dose is missed, take it as soon as remembered unless it is close to the next dose. Do not double doses.,The patch is not MRI compatible; remove it before any MRI, CT scan, or diathermy procedure. Inform all healthcare providers that you use this system. The patch contains no latex. You may feel a mild sensation when the patch communicates with your phone. Keep your phone nearby (within Bluetooth range) for recording.,Common side effects of aripiprazole include nausea, vomiting, constipation, headache, dizziness, insomnia, restlessness, and weight gain. Seek medical attention for severe muscle stiffness, fever, confusion, irregular heartbeat, or suicidal thoughts. Avoid alcohol and activities requiring mental alertness until you know how this medication affects you.,The ingestible sensor is generally safe, but if you have a sensitivity to copper, magnesium, or silicon, discuss with your doctor. The patch may cause skin irritation; if it persists, stop use and contact your provider.,Do not rely solely on the app to confirm ingestion; it is not a substitute for clinical judgment. Store tablets at room temperature, away from moisture and heat. Keep out of reach of children.
Take this medication with a fatty meal (e.g., eggs, avocado, nuts) to improve absorption.,Do not crush or chew the tablets; swallow them whole with water.,Complete the full course of therapy even if you feel better.,Report any signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea, or abdominal pain.,Avoid pregnancy during treatment and for at least 1 month after the last dose; use reliable contraception.,You may experience dizziness or blurred vision; avoid driving or operating machinery until you know how the drug affects you.,If you are breastfeeding, discuss with your doctor before taking this medication.
No interactions on record
"Albendazole inhibits the CYP3A4-mediated metabolism of clemastine, leading to increased plasma concentrations of clemastine. This can potentiate the anticholinergic and sedative effects of clemastine, including dry mouth, urinary retention, constipation, and drowsiness. Patients may experience heightened central nervous system depression, especially with concurrent use of other CNS depressants."
"Ranolazine, a piperazine derivative antianginal agent, is a moderate CYP3A4 inhibitor. Albendazole is primarily metabolized by CYP3A4 to its active metabolite, albendazole sulfoxide. Coadministration increases albendazole systemic exposure by approximately 50%, potentially enhancing both therapeutic efficacy and dose-dependent toxicities, including hepatotoxicity and bone marrow suppression."
"Albendazole inhibits CYP3A4, the enzyme primarily responsible for the metabolism of lovastatin. This inhibition reduces lovastatin clearance, leading to elevated plasma concentrations and increased risk of statin-related adverse effects such as myopathy, rhabdomyolysis, and hepatotoxicity. Patients receiving this combination should be monitored closely for signs of muscle pain or weakness and liver enzyme abnormalities."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ABILIFY MYCITE KIT vs ALBENDAZOLE, answered by our medical review team.
ABILIFY MYCITE KIT is a Atypical antipsychotic that works by Aripiprazole is a partial agonist at D2 and D3 dopamine receptors and 5-HT1A serotonin receptors, and an antagonist at 5-HT2A serotonin receptors. It also exhibits moderate affinity for histamine H1 receptors and alpha1-adrenergic receptors. The My Cite kit includes a sensor that detects tablet ingestion and transmits data to a wearable patch.. ALBENDAZOLE is a Anthelmintic that works by Albendazole inhibits tubulin polymerization by binding to beta-tubulin, disrupting microtubule formation, which leads to impaired glucose uptake and depletion of glycogen stores in susceptible parasites, resulting in their immobilization and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ABILIFY MYCITE KIT and ALBENDAZOLE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ABILIFY MYCITE KIT is: Oral: 10-15 mg once daily; dose range 5-30 mg/day; titrate based on response and tolerability. The MYCITE sensor is applied to the tablet; the patch and app are for adherence monitoring only.. The standard adult dose of ALBENDAZOLE is: 400 mg orally twice daily for 3-7 days for most indications; for neurocysticercosis, 400 mg orally twice daily for 8-30 days; for hydatid disease, 400 mg orally twice daily for 28-day cycles with 14-day drug-free intervals for 3 cycles.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ABILIFY MYCITE KIT and ALBENDAZOLE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ABILIFY MYCITE KIT is classified as Category C. First trimester: Limited human data; animal studies show developmental toxicity (reduced fetal weight, delayed ossification) at doses similar to human exposure. Second/third trimes. ALBENDAZOLE is classified as Category D/X. FDA Category C. First trimester: risk of skeletal abnormalities and embryotoxicity based on animal studies. Second and third trimesters: limited human data, but potential for fetal. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.